Introducing LIPECELTE® Trabectedin: A New Addition to Our Oncology Line

At Bioprofarma Bagó, we reaffirm our dedication to patient care with the launch of LIPECELTE® trabectedin, approved by ANMAT for the treatment of:

– Advanced soft tissue sarcoma (STS) in adult patients who have failed anthracycline and ifosfamide treatment or are not candidates for these therapies.
– Platinum-sensitive recurrent ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD).

LIPECELTE® is available in the following presentation:

– 1 mg vial (single-unit package)

With this new launch, Bioprofarma Bagó solidifies its commitment to healthcare professionals and patients, providing innovative, high-quality solutions that make a meaningful difference in patients’ lives.

Bioprofarma Bagó
Working in the present, thinking the future.